Breaking News

Japan July Consumer Prices Rise 3.3%, Meeting Estimates
Tweet TWEET

ResearchMoz.us: ENT Disorders Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6%

  ResearchMoz.us: ENT Disorders Market Forecast 2017 - Reach $17.2 billion,
                          Indicating a CAGR of 1.6%

  PR Newswire

  ALBANY, New York, September 11, 2013

ALBANY, New York, September 11, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Global ENT Disorders Market
Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6%

ResearchMoz announces that it has published a new study Global ENT Disorders
Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6%

The leading business intelligence provider, has released its latest research,
"ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to
Replace Older Therapies Due to Anti-Bacterial Resistance", which provides
in-depth analysis of the unmet needs, drivers and barriers that affect the
global ENT disorders therapeutics market. The report analyzes the markets for
ENT disorders in the US, the top five countries in Europe (the UK, Germany,
France, Italy and Spain) and Japan.

Treatment usage patterns, sales value and annual cost of therapy are forecast
until 2017 for key geographies in the five leading therapeutic segments.
Further, the report provides competitive benchmarking for the leading
companies and analyzes the mergers and acquisitions (M&A) and licensing
agreements that shape the global markets.

Browse Complete Report with TOC@ 
http://www.researchmoz.us/ent-disorders-market-to-2017--cephalosporins-quinolones-and-macrolides-to-replace-older-therapies-due-to-anti-bacterial-resistance-report.html


The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research's team of industry experts. Analysis shows that the ENT disorders
market will continue to grow marginally, largely due to the growing population
and deteriorating environmental conditions. The prime reasons for the slow
growth of the market are the generic domination and the weak product pipelines
for all five key indications. The global ENT disorders market was estimated to
be worth $15.3 billion in 2010, having grown at a compound annual growth rate
(CAGR) of 0.7% between 2002 and 2010. By 2017, the global ENT disorders market
is forecast to reach $17.2 billion, indicating a CAGR of 1.6% between 2010 and
2017.The ENT disorders M&A landscape has seen low levels of activity over the
last decade, with only 16 deals signed from 2004-2011. The therapeutic area of
focus for the M&A deals from 2004-2011 remained highly concentrated for
sinusitis. Some deals had multiple ENT disorders as their therapeutic area of
focus.

Scope

Annualized market data for the ENT disorders market from 2002 to 2010,
forecast forward to 2017.

Analysis of the leading therapeutic segments, including tonsillitis,
sinusitis, rhinitis, otitis media and tracheobronchitis.

Analysis of the ENT disorders market in the leading geographies globally,
which include the US, the UK, Germany, France, Italy, Spain and Japan.

Market characterization of the ENT disorders market, including market size,
annual cost of therapy and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in the various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in
this report are Abbott Laboratories, Bayer AG, Eli Lilly, GSK, J&J, Novartis
AG, Merck & Co., Pfizer and Sanofi.

Key M&A activities and licensing agreements that have taken place between 2004
and mid-2011 in the global ENT disorders market

Find More Reports of Surgical Equipment Market @
http://www.researchmoz.us/surgical-equipment-market-reports-53.html

Reasons to buy

Align your product portfolio to the markets with high growth potential.

Develop market-entry and market expansion strategies by identifying the
leading therapeutic segments and geographic markets poised for strong growth.

Reinforce R&D pipelines by identifying new target mechanisms that can produce
first-in-class molecules with more efficiency and better safety.

Develop key strategic initiatives by understanding the key focus areas of
leading companies.

Exploit in-licensing and out-licensing opportunities by identifying products
that could fill portfolio gaps.

Popular Market Research Reports Report:

US  Nurse Call System Equipment Market 2012-2016: Analysts forecast the Nurse
Call System Equipment market in the US to grow at a CAGR of 13.66 percent over
the period 2012-2016. One of the key factors contributing to this market
growth is the increasing elderly population. The Nurse Call System Equipment
market in the US has also been witnessing the integration of nurse call
systems with wireless technologies. However, the lack of awareness of advanced
technologies available could pose a challenge to the growth of this
market.TechNavio's report, the Nurse Call System Equipment Market in the US
2012-2016, has been prepared based on an in-depth market analysis with inputs
from industry experts. The report covers the Nurse Call System Equipment
market in the US landscape and its growth prospects in the coming years. The
report also includes a discussion of the key vendors operating in this market.
Browse Complete Report@ 
http://www.researchmoz.us/nurse-call-system-equipment-market-in-the-us-2012-2016-report.html

Mobile Phone Indoor Positioning Systems (IPS) and Real Time Locating Systems
(RTLS) 2013-2023: Indoor Positioning Systems (IPS) primarily concerns
location-based services on mobile phones where GPS does not work. The term
Real Time Locating Systems (RTLS) primarily concerns locating people and
things at a distance, securely, using second generation RFID. The subjects are
converging with Apple, Samsung, Google, Nokia, Microsoft, Hewlett Packard and
IBM clashing for the tens of millions of dollars of business that is emerging.
The first $0.5 billion order has been landed. This subject heavily involves
short range communications notably WiFi and Bluetooth and inertial navigation
and advanced RFID as it progresses to determining 3D position including
orientation and line of travel. Emergency services, healthcare, retailing,
manufacturing, logistics and many other industries will be transformed by what
is becoming possible. The winners in making and operating mobile phones will
offer the most compelling new functionality, IPS being a major enabler. The
winners in making, integrating and operating RTLS will reduce cost and improve
usefulness, not least to encompass mobile phones and other mobile computing.
The world's largest companies are locking horns on this. The topics of IPS and
RTLS embrace a value chain from research and consultancy to software,
services, hardware, integration and facilities management. Mobile phone app
developers and value added enhancements plus ecosystems of mobile phones, web
services and more are also involved. Browse Complete Report@ 
http://www.researchmoz.us/mobile-phone-indoor-positioning-systems-ips-and-real-time-locating-systems-rtls-2013-2023-report.html

###

Mobile Phone Insurance Revenue by Country & Region Database: 2013 - 2018 (
http://www.researchmoz.us/mobile-phone-insurance-revenue-by-country-and-region-database-2013-2018-report.html
) The mobile phone insurance industry is increasingly gaining momentum. As
device vendors intensely compete by launching new and unique Smartphone
models, insurance companies are heavily capitalizing on device specific
insurance plans. With global revenues of over $30 Billion in 2013, the
industry is set to grow at a CAGR of 17 % over the next five years. By 2018,
it is estimated that the industry would be worth $61 Billion. The "Mobile
Phone Insurance Revenue by Country & Region Database: 2013 - 2018" tracks
historical revenues and yearly forecasts for the global mobile insurance
industry at both country and regional levels. Browse Complete Report@
http://www.researchmoz.us/mobile-phone-insurance-revenue-by-country-and-region-database-2013-2018-report.html

###

The Taiwanese Mobile Phone Industry, 3Q 2013: Branded Vendors: This research
report presents mobile phone shipment volume forecast and recent quarter
review of major Taiwanese branded vendors. The report includes shipment volume
and value, ASP, vendor volume ranking, shipment by brands, and price trend.
Also provided are shipment breakdowns by system technology, operating system,
display technology, panel size, shipment destination, and production location.
The content of this report is based on primary data obtained through
interviews with Taiwanese mobile phone branded vendors. The report finds that
the shipment volume of Taiwanese mobile phone branded vendors grew
sequentially in the second quarter of 2013, mainly ascribed to resumed
production capacity following the relief to the shortage of high-end
components. Nevertheless, it is anticipated that without effective marketing
strategies in place, Taiwanese branded mobile phone shipment volume will
suffer from a double-digit decline in the second half of 2013 compared to the
first. Browse Complete Report@
http://www.researchmoz.us/the-taiwanese-mobile-phone-industry-3q-2013-branded-vendors-report.html

Table of Contents 1.1 List of Tables 1.2 List of Figures 2 ENT Disorders
Market - Introduction 2.1 GBI Research Report Guidance 3 ENT Disorders Market
- Market Overview 3.1 Rising Global Population and Deteriorating Environmental
Conditions Drive ENT Disorder Therapeutics 3.2 Gross Maldistribution 3.3 ENT
Disorders Marked By Antibiotic Overuse 3.4 Entry of New Players Restricted by
the Number of Generics and Stringent FDA Regulations 3.4.1 Ketolides - A New
Class of Antibacterials 3.5 Revenue Forecasts 3.6 Annual Cost of Therapy 3.7
Treatment Usage Patterns 3.7.1 Diseased Population 3.7.2 Treatment Seeking
Population 3.7.3 Diagnosed Population 3.7.4 Prescription Population 3.8
Drivers and Restraints of the ENT Disorders Market 3.8.1 ENT Disorders Market
Drivers 3.8.2 ENT Disorders Market Restraints 4 ENT Disorders Market -
Therapeutic Landscape 4.1 Tonsillitis Market 4.1.1 Introduction 4.1.2 Revenue
Forecasts 4.1.3 Annual Cost of Therapy 4.1.4 Treatment Flow Algorithm 4.1.5
Treatment Usage Patterns 4.1.6 Profiles of Key Drugs in the Tonsillitis Market
4.1.7 Geographical Segmentation 4.2 Sinusitis Market 4.2.1 Introduction 4.2.2
Revenue Forecasts 4.2.3 Annual Cost of Therapy 4.2.4 Treatment Flow Algorithm
4.2.5 Treatment Usage Patterns 4.2.6 Profiles of Key Drugs in the Sinusitis
Market 4.2.7 Geographical Segmentation 4.3 Rhinitis Market 4.3.1 Introduction
4.3.2 Revenue Forecasts 4.3.3 Annual Cost of Therapy 4.3.4 Treatment Flow
Algorithm 4.3.5 Treatment Usage Patterns 4.3.6 Profiles of Key Drugs in the
Rhinitis Market 4.3.7 Geographical Segmentation 4.4 Otitis Media Market 4.4.1
Introduction 4.4.2 Revenue Forecasts 4.4.3 Annual Cost of Therapy 4.4.4
Treatment Flow Algorithm 4.4.5 Treatment Usage Patterns 4.4.6 Profiles of Key
Drugs in the Otitis Media Market 4.4.7 Geographical Segmentation 4.5
Tracheobronchitis Market 4.5.1 Introduction 4.5.2 Revenue Forecasts 4.5.3
Annual Cost of Therapy 4.5.4 Treatment Flow Algorithm 4.5.5 Treatment Usage
Patterns 4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market 4.5.7
Geographical Segmentation 5 ENT Disorders Market - Geographical Landscape 5.1
The US 5.1.1 Revenue Forecasts 5.1.2 Annual Cost of Therapy 5.1.3 Treatment
Usage Patterns 5.2 Top Five Countries in Europe 5.2.1 Revenue Forecasts 5.2.2
Annual Cost of Therapy 5.2.3 Treatment Usage Patterns 5.3 Japan 5.3.1 Revenue
Forecasts 5.3.2 Annual Cost of Therapy 5.3.3 Treatment Usage Patterns 6 ENT
Disorders Market - Pipeline Analysis 6.1 Introduction 6.1.1 Research and
Development Pipeline - Tonsillitis 6.1.2 Research and Development Pipeline -
Sinusitis 6.1.3 Research and Development Pipeline - Rhinitis 6.1.4 Research
and Development Pipeline - Otitis Media 7 ENT Disorders Market - Competitive
Landscape 7.1 Competitive Profiling 7.1.1 Abbott Laboratories 7.1.2 Bayer AG
7.1.3 GlaxoSmithKline 7.1.4 Johnson & Johnson (J&J) 7.1.5 Merck & Co 7.1.6
Pfizer 7.1.7 Novartis AG 7.1.8 F. Hoffmann-La Roche Ltd. 7.1.9 Sanofi 8 ENT
Disorders Market - Strategic Consolidations 8.1 Overview 8.2 ENT Disorders
Market M&A Deals 8.2.1 M&A Deals by Geography 8.2.2 Deals by Type 8.2.3 Major
M&A Deals 8.3 R&D Licensing Agreements 8.3.1 Deals by Indication 8.3.2 Deals
by Geography 8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement
with Alcon Pharmaceuticals for Finafloxacin 9 ENT Disorders Market - Appendix
9.1 Market Definitions 9.2 Abbreviations 9.3 Research Methodology 9.3.1
Coverage 9.3.2 Secondary Research 9.3.3 Primary Research 9.3.4 Geographical
Landscape 9.3.5 Pipeline Analysis 9.3.6 Competitive Landscape 9.3.7 Expert
Panel Validation 9.4 Contact Us 9.5 Disclaimer 9.6 Sources

Browse Complete Report with TOC@ 
http://www.researchmoz.us/ent-disorders-market-to-2017--cephalosporins-quinolones-and-macrolides-to-replace-older-therapies-due-to-anti-bacterial-resistance-report.html

About Us

ResearchMoz is the one stop online destination to find and buy market research
reports & Industry Analysis . We fulfill all your research needs spanning
across industry verticals with our huge collection of market research reports.
We provide our services to all sizes of organizations and across all industry
verticals and markets. Our Research Coordinators have in-depth knowledge of
reports as well as publishers and will assist you in making an informed
decision by giving you unbiased and deep insights on which reports will
satisfy your needs at the best price.

Contact M/s Sheela 90 Sate Street, Suite 700Albany, NY 12207 Tel:
+1-518-618-1030USA - Canada Toll Free: 866-997-4948 Email:
sales@researchmoz.com http://www.researchmoz.us/
http://www.researchmoz.blogspot.com/
 
Press spacebar to pause and continue. Press esc to stop.